Skip to main navigation

Skip to main content

Home

Home

About

About Liquidia

Products and Pipeline

Pipeline and Products

IR Nav

Investors

Careers

Careers
- Overview
- Jobs
- Benefits
- Principles

Contact Us

Contact Us
- Overview
- Map/Directions

Event

IR Nav

Investors

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
Corporate Governance
Documents & Charters Leadership Board of Directors Committee Composition
SEC Filings
IR Resources
Investor FAQs IR Contact Email Alerts Proxy Online

Liquidia First Quarter 2022 Financial Results and Corporate Update Call

May 12, 2022 at 8:30 AM EDT

IR Tools

Print Page
Share
RSS

Request Email Alerts

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2023 Liquidia Corporation All Rights Reserved.

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection.

Legal Nav

Legal
Privacy
Cookies
Social Media

Facebook
Twitter
LinkedIn